# DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)

> **NCT06805305** · PHASE2 · RECRUITING · sponsor: **Diakonos Oncology Corporation** · enrollment: 180 (estimated)

## Conditions studied

- Glioblastoma (GBM)

## Interventions

- **BIOLOGICAL:** DOC1021
- **PROCEDURE:** Tumor resection
- **DRUG:** Temodar (Temozolomide)
- **RADIATION:** SOC cranial radiation

## Key facts

- **NCT ID:** NCT06805305
- **Lead sponsor:** Diakonos Oncology Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-17
- **Primary completion:** 2030-03
- **Final completion:** 2032-03
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06805305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06805305, "DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06805305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*